Alpha 2-adrenergic activity is normal in patients with thyroid disease

Area of Science:

• Endocrinology
• Cardiovascular Physiology
• Neuroscience

Background:

• Thyroid dysfunction is linked to altered sympathetic nervous system activity.
• Previous research noted changes in alpha 1 and beta-adrenergic receptor sensitivity in thyroid disease.
• The alpha 2-adrenergic pathway's role in thyroid disease remains uncharacterized.

Purpose of the Study:

• To evaluate alpha 2-adrenergic activity in patients with thyroid disease.
• To assess cardiovascular and catecholamine responses to clonidine, a central alpha 2 adrenergic agonist.
• To investigate the alpha 2-adrenergic pathway's function in hypothyroidism and hyperthyroidism.

Main Methods:

• Study included 10 hypothyroid, 6 hyperthyroid, and 10 healthy subjects.
• Clonidine (4 micrograms/kg) was administered orally.
• Blood pressure, pulse rate, and catecholamine levels (noradrenaline, adrenaline) were measured before and after clonidine.

Main Results:

• Plasma noradrenaline decrease after clonidine was similar in hypothyroid, hyperthyroid, and control groups.
• No significant differences were observed in adrenaline or mean arterial pressure (MAP) response to clonidine.
• Therapy in hypothyroid patients reduced basal noradrenaline and blunted the MAP fall post-clonidine.

Conclusions:

• The inhibitory alpha 2-adrenergic receptor pathway appears to be normal in patients with altered thyroid function.
• Despite known alpha 1 and beta-adrenergic abnormalities, alpha 2-adrenergic function remains intact.
• Thyroid status does not impair the central alpha 2-adrenergic regulatory mechanism.